Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

NICE rejects stomach cancer drug

  • Comment

NICE has ruled against the use of trastuzumab (Herceptin) to treat stomach cancer, because of uncertainty over how long the drug can extend life.

In draft guidance NICE said that although trials do show that trastuzumab can extend life for some patients with gastric cancer, the data is not clear how long this extension will be. The guidance is out for public consultation until 27 July.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.